Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Double-blind, Randomized, Placebo-controlled, 4-Armed Parallel Group Study to Evaluate the Efficacy of Zolmitriptan 0.5-, 2.5- and 5-mg Nasal Spray in the Treatment of Acute Migraine Headache in Adolescents

Next Previous
Trial Profile

A Multicenter, Double-blind, Randomized, Placebo-controlled, 4-Armed Parallel Group Study to Evaluate the Efficacy of Zolmitriptan 0.5-, 2.5- and 5-mg Nasal Spray in the Treatment of Acute Migraine Headache in Adolescents

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zolmitriptan (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Acronyms TEENZ
  • Sponsors AstraZeneca

Most Recent Events

  • 10 Sep 2017 Results of a post hoc analysis (n= 656) evaluating the effect of baseline preventive medications on the safety and efficacy of Zolmitriptan Nasal Spray presented at the 2017 International Headache Society.
  • 07 Sep 2017 Trial design and post-hoc analysis data comparing placebo responders versus non-responders during single-blind placebo run-in period, presented at the 2017 International Headache Society.
  • 11 Jun 2017 Results assessing the effect of age on the effectiveness of zolmitriptan nasal spray in adolescent migraine, using age subgroups of younger (12-14 years) and older (15-17 years) adolescents, presented at the 59th Annual Scientific Meeting of the American Headache Society.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top